GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (OTCPK:SBHMY) » Definitions » Median PS Value

SBHMY (Sino Biopharmaceutical) Median PS Value : $15.22 (As of Dec. 11, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Sino Biopharmaceutical Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Sino Biopharmaceutical's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $4.173. Sino Biopharmaceutical's 10-Year median PS Ratio is 3.6473. Therefore, the Median PS Value for today is $15.22.

As of today (2024-12-11), Sino Biopharmaceutical's share price is $9.05. Sino Biopharmaceutical's Median PS Value is $15.22. Therefore, Sino Biopharmaceutical's Price to Median PS Value for today is 0.59.

The historical rank and industry rank for Sino Biopharmaceutical's Median PS Value or its related term are showing as below:

SBHMY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.59   Med: 0.95   Max: 3.27
Current: 0.59

During the past 13 years, the highest Price to Median PS Value of Sino Biopharmaceutical was 3.27. The lowest was 0.59. And the median was 0.95.

SBHMY's Price-to-Median-PS-Value is ranked better than
58.33% of 264 companies
in the Biotechnology industry
Industry Median: 0.695 vs SBHMY: 0.59

Sino Biopharmaceutical Median PS Value Historical Data

The historical data trend for Sino Biopharmaceutical's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Median PS Value Chart

Sino Biopharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.43 12.61 17.08 14.58 15.33

Sino Biopharmaceutical Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 14.58 - 15.33 -

Competitive Comparison of Sino Biopharmaceutical's Median PS Value

For the Biotechnology subindustry, Sino Biopharmaceutical's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sino Biopharmaceutical's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Sino Biopharmaceutical's Price-to-Median-PS-Value falls into.



Sino Biopharmaceutical Median PS Value Calculation

Sino Biopharmaceutical's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=4.173*3.6473
=15.22

10-Year Median PS Ratio is 3.6473.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sino Biopharmaceutical's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $4.173.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sino Biopharmaceutical  (OTCPK:SBHMY) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Sino Biopharmaceutical's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=9.05/15.22
=0.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sino Biopharmaceutical Median PS Value Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Sino Biopharmaceutical Business Description

Traded in Other Exchanges
Address
1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2023, 37.8% of the firm's total revenue comes from five innovative drugs and five biosimilar drugs. Sino Biopharm's biggest revenue segment is oncology medicines, accounting for 33.6% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.

Sino Biopharmaceutical Headlines

From GuruFocus

Sino Biopharmaceutical Ltd's Dividend Analysis

By GuruFocus Research 06-11-2024

Value Idea Contest: Sino Biopharmaceutical

By Matthew Sipos Matthew Sipos 01-10-2019

Matthews China Fund Comments on Sino Biopharmaceutical

By Sydnee Gatewood Sydnee Gatewood 10-25-2019

GuruFocus Value Idea Contest Sees 2 Winners!

By Holly LaFon Holly LaFon 07-12-2019

Matthews China Fund Comments on Sino Biopharmaceutical

By Vera Yuan Vera Yuan 10-20-2014

Matthews China Fund Comments on Sino Biopharmaceutical

By Sydnee Gatewood Sydnee Gatewood 01-28-2020

Matthews China Fund 3rd Quarter Commentary

By Holly LaFon Holly LaFon 10-19-2017